FDA Grants Breakthrough Device Designation to Glytec's Glucommander Pediatrics for Insulin Dosing in Newborns and Infants
核心洞察
The FDA has granted Breakthrough Device Designation to Glucommander Pediatrics (搜索), a proposed insulin dosing recommendation algorithm for hospitalized neonates and infants under two years of age.
No insulin dosing recommendation software has been FDA-cleared for this population, which includes newborns and premature infants with unstable physiology and few available tools.
The prescription-only product is intended for infants requiring continuous intravenous insulin infusion for conditions such as diabetic ketoacidosis (搜索), hyperglycemic hyperosmolar state (搜索) and hyperglycemia of prematurity (搜索).
Glytec (搜索) announced on Sept. 24, 2026 that the U.S. Food and Drug Administration has granted Breakthrough Device Designation for Glucommander Pediatrics (搜索), a proposed insulin dosing recommendation algorithm for hospitalized neonates and infants from birth to less than two years of age. The designation covers a population for which no insulin dosing recommendation software has been FDA-cleared.
Glucommander Pediatrics (搜索) is designed as a separate, prescription-only product for hospitalized neonates and infants who require continuous intravenous insulin infusion for life-threatening or irreversibly debilitating conditions. The intended indications include diabetic ketoacidosis (搜索), hyperglycemic hyperosmolar state (搜索), hyperglycemia of prematurity (搜索), and persistent hyperglycemia (搜索) in critically ill patients receiving intensive care. The product would extend the Glucommander (搜索) technology into the neonatal intensive care unit and the pediatric intensive care unit.
Clinical Rationale in a High-Risk Population
Hyperglycemia (搜索) is common in critically ill newborns and premature infants and is associated with poor outcomes in this population. Continuous intravenous insulin infusion is the standard of care, and insulin is classified as a high-alert medication in every hospital setting. The margin for dosing error narrows as patient weight falls.
In adult intensive care, technology-enabled insulin titration protocols have been shown to improve glucose control and reduce hypoglycemia compared with manual, paper protocols. Glytec (搜索) frames the goal for Glucommander Pediatrics (搜索) as extending that approach to infants under the age of two.
"Glucose values are among the most frequently collected measures in hospitalized patients, recorded across nearly every unit and service line. Care for newborns and infants sits at the far end of that problem, where the physiology is least stable and the available tools are fewest," said Patrick Cua, CEO of Glytec (搜索). "We have spent twenty years making insulin dosing safer for hospitalized patients, and the smallest patients have been last in line the entire time."
Regulatory Pathway and Platform History
FDA's Breakthrough Devices Program is intended to give patients and clinicians more timely access to technologies that may offer more effective treatment for life-threatening or irreversibly debilitating conditions.
Glucommander (搜索) has been FDA-cleared since 2006, and Glytec (搜索) serves more than 400 hospitals and health systems. Since the first clearance, the company has expanded the platform through multiple successive clearances covering both intravenous and subcutaneous insulin dosing, with pediatric use extended to patients ages 2 to 17 beginning in 2012. Glucommander is available by prescription only.